Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Beijing QL Biopharmaceutical Co.,Ltd
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07550816CT.gov Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants | — | Not Yet Recruiting | — | — | — |
NCT07502001CT.gov Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin | — | Not Yet Recruiting | — | — | — |
NCT07331389CT.gov A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin | — | Recruiting | — | — | — |
NCT07362030CT.gov Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin | — | Active Not Recruiting | — | — | — |
NCT06920056CT.gov A Study of BGM0504 in Overweight or Obese Participants | — | Completed | — | — | — |
NCT06289504CT.gov A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight | — | Completed | — | — | — |
NCT05815680CT.gov A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects | — | Completed | — | — | — |
NCT05445232CT.gov A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Warfarin (this asset) | Beijing QL Biopharmaceutical Co.,Ltd | P1 | CC · 46 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Warfarin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Venous Thromboembolism | — | P4 | A · 81 |
| Atrial Fibrillation | — | P4 | BBB · 77 |
| Hemorrhagic Disease | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Warfarin in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/warfarin-obesity-disorder-19241
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →